SYNLOGIC, INC. Impairment of Long-Lived Assets Held-for-use
SYNLOGIC, INC. (SYBX) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-12
- SYNLOGIC, INC. impairment of long-lived assets held-for-use for the quarter ending 2025-12-31 was $0.00.
- SYNLOGIC, INC. impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00.
- SYNLOGIC, INC. impairment of long-lived assets held-for-use for the quarter ending 2025-06-30 was $0.00.
- SYNLOGIC, INC. impairment of long-lived assets held-for-use for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- SYNLOGIC, INC. impairment of long-lived assets held-for-use for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SYNLOGIC, INC. impairment of long-lived assets held-for-use for fiscal 2024 was $5.01M.
- SYNLOGIC, INC. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
- SYNLOGIC, INC. impairment of long-lived assets held-for-use for fiscal 2015 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | -$382.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | -$382.00K derived: sum of 3 quarters · filed 2026-03-12 | $5.01M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$382.00K derived: sum of 2 quarters · filed 2025-11-13 | $5.01M 10-Q · filed 2025-11-13 | $5.01M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$382.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.01M 10-Q · filed 2025-08-07 | $5.01M derived: sum of 3 quarters · filed 2025-08-07 | $5.01M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $5.39M 10-Q · filed 2025-05-08 | $5.39M derived: sum of 2 quarters · filed 2025-05-08 | $5.39M derived: sum of 3 quarters · filed 2025-05-08 | $5.39M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 derived: sum of 3 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | |||
| 2015-12-31 | $0.00 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |